Bahr U, Schulten H R, Hommes O R, Aerts F
Clin Chim Acta. 1980 Apr 25;103(2):183-92. doi: 10.1016/0009-8981(80)90212-0.
The levels of cyclophosphamide in samples of urine, serum and cerebrospinal fluid of multiple sclerosis patients, who had received the drug orally (4 x 100 mg/day) have been determined by field desorption mass spectrometry using the principle of stable isotope dilution. After thorough preparation of the samples, concentrations of cyclophosphamide of 10 to 60 micrograms/ml in urine and 200 to 400 ng/ml in serum and cerebrospinal fluid have been determined from 0.6-3 ml samples. The first quantitative data for cyclophosphamide in cerebrospinal fluid of multiple sclerosis patients could be established without the use of radioactive material. The relatively high level of the parent drug found in the fluid at the end of a 3-weeks treatment may shed some light on the mechanism of action of this drug in the treatment of the disease.
采用稳定同位素稀释原理，通过场解吸质谱法测定了口服环磷酰胺（4×100mg/天）的多发性硬化症患者尿液、血清和脑脊液样本中环磷酰胺的含量。样本经过充分制备后，从0.6 - 3ml的样本中测定出尿液中环磷酰胺浓度为10至60微克/毫升，血清和脑脊液中为200至400纳克/毫升。无需使用放射性物质即可得出多发性硬化症患者脑脊液中环磷酰胺的首批定量数据。在为期3周的治疗结束时，在脑脊液中发现的母体药物水平相对较高，这可能有助于揭示该药物治疗该疾病的作用机制。
